News and Press

ACELYRIN, INC. Hosts KOL Panel Discussion at ACR Convergence 2022 on Role of Enthesitis in PsA and AxSpA
November 29, 2022

ACELYRIN, INC. Hosts KOL Panel Discussion at ACR Convergence 2022 on Role of Enthesitis in PsA and AxSpA.

ACELYRIN, INC. Adds Two Veteran C-suite Leaders
November 10, 2022

ACELYRIN, INC., a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced two executive appointments that will strengthen leadership of key corporate functions as the company enters its next stage of growth.

ACELYRIN, INC. Announces Phase 2 Data for Izokibep in Psoriatic Arthritis That Demonstrate Broad Clinical Efficacy – including in Difficult-to-Treat Manifestations – Driving Meaningful Benefits for Patients Such as Improved Pain, Sleep, and Physical Function
November 08, 2022

ACELYRIN, INC., a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced additional data from a phase 2 trial of izokibep in psoriatic arthritis.

ACELYRIN, INC. to Present at Upcoming Investor Conferences
November 03, 2022

ACELYRIN, INC., a late-stage biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that its Co-founder and Chief Executive Officer Shao-Lee Lin, MD, PhD will present at the following upcoming investor conferences.